Randomized controlled trial2025Open access

The effectiveness of red-light therapy on myopia control depends on its direct effect: a mediation analysis

Chen Q, Wei H, Soh ZD, Zhu Q, Shao X, Xue C, Li H, Tao Y, Hu M, Cheng CY, Zhong H

Journal of translational medicine · 4 citations

How it was studied

Design
Randomized controlled trial (indexed by PubMed)
Studied in
People
Main outcome
Health markers and function

Who paid for it

Funding
Independent funding
Government
National Natural Science Foundation of China-Yunnan Joint Fund
Grants
National Natural Science Foundation of China-Yunnan Joint Fund (82360212)

Based on 1 listed funder(s) and full-text disclosure statement.

Publication

Published
2025-12-02 · J Transl Med · vol. 24 · issue 1 · p. 34
Publisher
BioMed Central
Cited
2 citations · more than 82% of similar papers · 1.2× the field average
References
44 works
Access
Open access (journal) · CC-BY-NC-ND
Research areas
Ophthalmology and Visual Impairment Studies · Retinopathy of Prematurity Studies · Retinal Diseases and Treatments
Keywords
Peripheral, Refraction, Mediation, Retinal, Randomized controlled trial, Choroid, Refractive error
MeSH
choroid, humans, myopia, refraction, ocular, treatment outcome, child, female, male, red light

11 authors

From CN, SG

  • Qin ChenNanjing Medical University
  • Hongyu WeiKunming Medical University; Singapore Eye Research Institute; First Affiliated Hospital of Kunming Medical University
  • Zhi Da SohSingapore Eye Research Institute
  • Qin ZhuYunnan University; Second People's Hospital of Yunnan Province
  • Xian ShaoKunming Medical University; First Affiliated Hospital of Kunming Medical University
  • Cancan XueSingapore Eye Research Institute

Abstract

PURPOSE: To investigate whether alterations in subfoveal choroidal thickness (SFCT) and peripheral retinal refraction mediate the efficacy of repeated low-level red-light (RLRL) therapy for myopia control. METHODS: We conducted a mediation analysis within a multicenter, randomized controlled trial. A total of 300 myopic children were included in this analysis. Participants in RLRL group wore single-vision spectacles (SVSs) and received red-light therapy twice daily for 12 months. The control group wore SVSs only, without any additional myopia-control intervention. Axial length (AL), spherical equivalent refraction (SER), SFCT and total refractive difference value (TRDV) were measured at baseline and at follow-up visits over 12 months. RESULTS: After 12 months, RLRL therapy significantly attenuated axial length and myopic shift in spherical equivalence compared with controls, accompanied by sustained increases in choroidal thickness and reductions in peripheral hyperopic defocus. Mediation analysis revealed that changes in choroidal thickness and peripheral refraction accounted for 24.83% and 6.79%, respectively, of the effect on axial length inhibition, and 28.79% and 5.97% of the effect on spherical equivalent control. The remaining effects were attributable to the direct impact of red-light (68.39% for axial length and 65.24% for spherical equivalence). Notably, choroidal thickening emerged as the predominant mediator within the first three months. CONCLUSIONS: RLRL therapy exerted a predominantly direct effect on myopia control, while changes in choroidal thickness and peripheral defocus partially mediated its effectiveness. TRIAL REGISTRATION: This trial was registered at the Chinese Clinical Trial Registry on January 30, 2021, with trial registration number: ChiCTR2100042836. https://www.chictr.org.cn/showprojEN.html?proj=120971 .

Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).

Community trust

Loading…

How much do you trust this study's findings?

0 · not at all10 · completely

Comments

Sign in to rate, comment on or flag this study.Sign in

Something wrong here?

Flag this study if its information, labels or funding look wrong. An editor reviews every flag.

Sign in to rate, comment on or flag this study.Sign in

Educational information about published research. Not medical advice, and not a recommendation to start or stop anything.